Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04073173
Other study ID # StrAAS
Secondary ID 2020-004269-38
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date November 1, 2020
Est. completion date October 31, 2022

Study information

Verified date September 2020
Source Ospedali Riuniti Ancona
Contact Virgilio Carnielli, MD, PHD
Phone +390715962045
Email v.carnielli@staff.univpm.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare stress, changes in oxygenation and oxidative damage in preterm infants with respiratory distress syndrome (RDS) randomized to receive or not remifentanil as an analgesic drug during the administration of porcine surfactant (poractant alfa, Curosurf®) through the traditional (INSURE) or the less invasive (LISA) method.


Description:

At present, LISA and INSURE are both used for surfactant therapy in infants as comparable methods. However, a clear policy of using analgesics during surfactant therapy is still lacking: some neonatologists use analgesics to reduce stress and pain scores, whereas others do not approve their use due to interference with spontaneous breathing.

In this open-label, randomized, phase 4 clinical trial, infants admitted to our neonatal intensive unit care (NICU) will be evaluated according to the selection criteria and then randomized to receive or not remifentanil as an analgesic drug during the administration of porcine surfactant (poractant alfa, Curosurf®) via the INSURE or LISA method: Group-1) LISA-analgesic; Group 2) LISA-no analgesic; Group-3) INSURE-analgesic; Group-4) INSURE-no analgesic. Study patients will be stratified by gestational age at birth: Block A) 23.0-27.6 weeks of gestation; Block B) 28.0-31.6 weeks of gestation.

Early caffeine administration will be provided according to our NICU guidelines shortly after birth. Infants with adequate respiratory drive will be stabilized on nasal continuous positive airway pressure (CPAP; 4-8 cm of water) right after birth. Oxygen saturation targets will be 90-94%; moderate degrees of hypercarbia (PaCO2 < 60 mmHg, provided arterial pH >7.22) will be tolerated. Conditions mimicking respiratory distress syndrome (RDS; i.e. sepsis, air leaks, aspiration pneumonia, congenital heart disease) will be ruled out. RDS diagnosis will be clinical according to the European Guidelines. Nasal CPAP, bi-level CPAP or nasal intermittent positive pressure ventilation (synchronized or not) will be used at the discretion of the attending physician to stabilize the patients. Intubation criteria according to our NICU guidelines will be:

1. severe acidosis (defined as arterial pH<7.20 with a partial pressure of carbon dioxide (PaCO2) > 55 mmHg and partial pressure of oxygen (PaO2) < 50 mmHg) with a fraction of inspired oxygen (FiO2) > 0.50;

2. severe apnoea.

Enrolled infants will be evaluated from birth to day 7 of the hospital stay.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date October 31, 2022
Est. primary completion date October 31, 2022
Accepts healthy volunteers No
Gender All
Age group 168 Days to 223 Days
Eligibility Inclusion Criteria:

- gestational age at birth between 168 and 223 days,

- respiratory distress syndrome (diagnosed on the basis of clinical and/or radiological grounds) with a fraction of inspired oxygen =0.30 (for infants born =26 weeks' gestational age) or =0.40 (for infants born >26 weeks' gestational age) to achieve a peripheral oxygen saturation of 90-94% within 24 hours of life and good respiratory drive,

- written informed consent.

Exclusion Criteria:

- major malformations,

- late admission (after 24 hours of life),

- intubation in the delivery room,

- severe birth asphyxia,

- prolonged rupture of membranes,

- air leaks,

- no informed consent.

Study Design


Related Conditions & MeSH terms

  • Respiratory Distress Syndrome in Premature Infants
  • Respiratory Distress Syndrome, Adult
  • Respiratory Distress Syndrome, Newborn
  • Syndrome

Intervention

Procedure:
INSURE
Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.
LISA
Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.
Drug:
Analgesic, Opioid
Remifentanil (0.5-2 micrograms/kg/dose)

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Virgilio Paolo Carnielli Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona, Istituto di Ricerca Pediatrica Città della Speranza

References & Publications (6)

Badiee Z, Vakiliamini M, Mohammadizadeh M. Remifentanil for endotracheal intubation in premature infants: A randomized controlled trial. J Res Pharm Pract. 2013 Apr;2(2):75-82. doi: 10.4103/2279-042X.117387. — View Citation

Guinsburg R, Kopelman BI, Anand KJ, de Almeida MF, Peres Cde A, Miyoshi MH. Physiological, hormonal, and behavioral responses to a single fentanyl dose in intubated and ventilated preterm neonates. J Pediatr. 1998 Jun;132(6):954-9. — View Citation

Guinsburg R, Kopelman BI, de Almeida MF, Miyoshi MH. [Pain in intubated and ventilated preterm neonate: multidimensional assessment and response to fentanyl analgesia]. J Pediatr (Rio J). 1994 Mar-Apr;70(2):82-90. Portuguese. — View Citation

Lago P, Benini F, Agosto C, Zacchello F. Randomised controlled trial of low dose fentanyl infusion in preterm infants with hyaline membrane disease. Arch Dis Child Fetal Neonatal Ed. 1998 Nov;79(3):F194-7. — View Citation

Okamura H, Kinoshita M, Saitsu H, Kanda H, Iwata S, Maeno Y, Matsuishi T, Iwata O. Noninvasive surrogate markers for plasma cortisol in newborn infants: utility of urine and saliva samples and caution for venipuncture blood samples. J Clin Endocrinol Metab. 2014 Oct;99(10):E2020-4. doi: 10.1210/jc.2014-2009. Epub 2014 Jul 31. — View Citation

Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GH, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update. Neonatology. 2017;111(2):107-125. doi: 10.1159/000448985. Epub 2016 Sep 21. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cortisol concentrations Cortisol concentrations will be assessed in saliva, as salivary cortisol levels have been shown to be useful surrogate markers for plasma cortisol levels in neonates. Saliva samples will be collected using an absorbent swab stick, centrifuged at 4000 rpm for 10 minutes and kept at -80°C until assayed (minimum sample volume 25 µl). Enzyme immunoassay (ELISA kit) will be used. Basal samples will be obtained at the hospital admission and right before surfactant. At 1, 3, 6 12, 24 hours after surfactant administration and then daily in the first week at the same time of the day (to avoid circadian variations).
Secondary Galvanic Skin Responses An instrumental stress-test device measuring galvanic skin conductance will be used (Pain Monitor, Med-Storm, Norway): three electrodes will be attached to the infant's foot (sole and sides of the ankle); skin conductance is measured in micro Siemens (µS). At 1, 3, 6 12, 24 hours after surfactant administration and then daily in the first week at the same time of the day (to avoid circadian variations).
Secondary Heart rate Cardiac monitoring will assess heart rate. Traces will be saved onto a computer with a sampling frequency of 1 Hertz. Average heart rate, periods of tachycardia (>160 bpm for =5 seconds) and bradycardia (<100 bpm for =5 seconds) will be recorded. These parameters may be correlated with stress and hemodynamic instability during the procedures. 6 hours before and after surfactant therapy will be analyzed.
Secondary Brain oxygenation Brain oxygenation will be assessed by near-infrared spectroscopy (NIRS). From the hospital admission to day 7 of the hospital stay.
Secondary Oxygen saturation (SpO2) High precision oxygenation assessment will be attained by high frequency (1 Hz) sampling of SpO2 data from the cardio monitor to a computer, possibly by using multiple pulse oximeters in the same patient. From the hospital admission to day 7 of the hospital stay.
Secondary Markers of oxidative stress 8-isoprostane and nitrites/nitrates will be dosed on urine samples. At the hospital admission and at 6 and 12 hours after surfactant therapy.
See also
  Status Clinical Trial Phase
Completed NCT01651637 - First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome Phase 1
Terminated NCT02939742 - Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity? Phase 2/Phase 3
Completed NCT02770976 - Respiratory Pattern During Neurally Adjusted Ventilator Assist (NAVA) in Preterm Infants N/A
Completed NCT02661256 - Effect of Nasal Continuous Positive Airway Pressure on The Pharyngeal Swallow in Neonates N/A
Active, not recruiting NCT02445040 - Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates N/A
Completed NCT01962818 - High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Lung Volume Monitored by Electric Tomography Impedance. N/A
Not yet recruiting NCT02200900 - Study of Respiratory Physiology During High Flow Nasal Cannula Treatment in Preterm Neonates. N/A
Completed NCT02210026 - Seattle-PAP Bubble Nasal CPAP and Work of Breathing Phase 1
Completed NCT02396693 - Successful Extubation and Noninvasive Ventilation in Preterm ≤ 1500g Terms N/A
Completed NCT01220687 - Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation N/A